The use of a single pulse of intravenous methylprednisolone in the treatment of corneal graft rejection. A preliminary report.
In corneal graft rejection, rapid reversal of the rejection process is necessary to minimise endothelial cell loss. Ten consecutive patients with acute endothelial rejection were treated with a single 500 mg pulse of methylprednisolone intravenously and topical prednisolone 1% drops hourly. The rejection episode was successfully reversed in eight (80%) of the 10 grafts. This preliminary trial indicates that cortico-steroid pulse therapy may be beneficial in the management of severe corneal graft rejection with the advantage of avoiding prolonged oral corticosteroid therapy.
Hill
J C
JC
Department of Ophthalmology, Groote Schuur Hospital, Cape Town, South Africa.
Maske
R
R
Watson
P G
PG
D000293:Adolescent; D000328:Adult; D000368:Aged; D016039:Corneal Transplantation; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011239:Prednisolone / Q000627:therapeutic use
D011239:Prednisolone; D008775:Methylprednisolone